Intrahepatic Cholestasis of Pregnancy Supportive Care Protocol
Primary Stack
Core supplements with strongest evidenceSupports liver methylation and bile acid metabolism; may reduce symptoms and improve liver function
Primary treatment; reduces bile acid levels and improves liver function (prescription)
Supporting Studies (1)
Supporting Stack
Additional supplements for enhanced resultsMay be depleted in cholestasis due to fat malabsorption; supports clotting and fetal bone development
Supporting Studies (1)
Absorption may be impaired in cholestasis; supports maternal and fetal bone health
Supporting Studies (1)
Fat-soluble vitamin that may be depleted in cholestasis; antioxidant protection
Supporting Studies (1)
Supports fetal development; may have anti-inflammatory effects
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Intrahepatic Cholestasis of Pregnancy (ICP) is a liver condition that occurs in the third trimester, causing intense itching (especially on the palms and soles) due to elevated bile acids in the blood. ICP affects about 1% of pregnancies and is associated with increased risks of preterm birth, fetal distress, and stillbirth if not managed. The condition resolves after delivery but may recur in future pregnancies.
CRITICAL: ICP requires medical management and close monitoring. The primary treatment is ursodeoxycholic acid (UDCA), a prescription medication that reduces bile acid levels and improves outcomes. Fetal monitoring (non-stress tests, sometimes biophysical profiles) is essential, and early delivery (typically 36-37 weeks) is often recommended depending on bile acid levels and other factors. These supplements may provide additional support but DO NOT replace UDCA therapy or obstetric monitoring. Inform your obstetrician about all symptoms - severe itching should prompt bile acid testing.
* S-Adenosylmethionine (SAMe) supports liver methylation pathways involved in bile acid metabolism. Meta-analyses show SAMe can reduce symptoms (itching, liver enzymes) in ICP, sometimes used in combination with UDCA.
* Ursodeoxycholic Acid (UDCA) is the primary treatment (prescription medication included here for completeness). It's a bile acid that reduces toxic bile acid levels and has been shown to improve maternal symptoms and possibly fetal outcomes.
* Vitamin K may be depleted in cholestasis due to reduced bile salts impairing fat absorption. Supplementation is important to prevent bleeding complications in mother and baby.
* Vitamin D absorption may also be impaired. Maintaining adequate levels supports maternal and fetal bone health.
* Vitamin E is another fat-soluble vitamin that may be affected by cholestasis.
* Omega-3 Fatty Acids support fetal brain and eye development and may have anti-inflammatory effects.
Expected timeline: SAMe effects may be noticed within 2-3 weeks. UDCA typically improves itching and bile acids within 1-2 weeks. ICP resolves quickly after delivery.
Clinical Perspective
Intrahepatic Cholestasis of Pregnancy: elevated serum bile acids (≥10 µmol/L) with pruritus, typically third trimester. Pruritus characteristically on palms and soles, worse at night. Risk factors: family history, twin pregnancy, IVF, history of ICP, hepatitis C, northern European/South American ancestry. Fetal risks: preterm birth, meconium staining, fetal distress, stillbirth (risk correlates with bile acid levels, significant when >40 µmol/L). Maternal risks: vitamin K deficiency, postpartum hemorrhage.
CRITICAL: Management: UDCA 10-15mg/kg/day is standard treatment - reduces bile acids, improves pruritus, may improve outcomes. Monitoring: bile acids, LFTs weekly. Fetal surveillance: NST 1-2x weekly, consider BPP. Timing of delivery: 36-37 weeks if bile acids <100 µmol/L, earlier if >100 or other complications. Vitamin K supplementation recommended. SAMe may be adjunctive. Dexamethasone for fetal lung maturity if early delivery planned. Immediate delivery if bile acids >100 or fetal concerns.
* SAMe (B-grade): Methylation support; bile acid metabolism. Meta-analysis: reduces pruritus and improves biochemical markers (PMID: 23415616). Systematic review: beneficial in ICP (PMID: 15106249). 800-1600mg daily divided.
* UDCA (A-grade): Hydrophilic bile acid; displaces toxic acids. Cochrane review: standard treatment for ICP (PMID: 22674921). 10-15mg/kg/day. Prescription medication.
* Vitamin K (B-grade): Fat-soluble vitamin; clotting. Review: depletion in cholestasis (PMID: 17636792). 2.5-10mg daily orally. Some give to neonate also.
* Vitamin D (C-grade): May be depleted. Review: fat-soluble vitamins in cholestasis (PMID: 25623312). 2000-4000 IU daily.
* Vitamin E (C-grade): Antioxidant; fat-soluble. Review: in pregnancy complications (PMID: 19664096). 200-400 IU daily.
* Omega-3 Fatty Acids (C-grade): Fetal development. Review: pregnancy benefits (PMID: 24965308). 1-2g DHA+EPA daily.
Biomarker targets: Serum bile acids (goal reduction, ideally <40 µmol/L), ALT, AST, bilirubin, prothrombin time/INR, pruritus severity.
Protocol notes: Start UDCA immediately upon diagnosis. SAMe can be added, particularly if UDCA alone insufficient. Monitor bile acids and LFTs weekly. Pruritus management: emollients, cool baths, antihistamines (limited efficacy for ICP itch), cholestyramine (second-line, can worsen vitamin K deficiency). Fetal monitoring: NST 1-2x weekly from diagnosis. Amniocentesis for fetal lung maturity rarely needed now. Delivery timing based on bile acid levels and fetal/maternal status. Postpartum: symptoms resolve quickly, LFTs normalize within days to weeks. Check LFTs 6 weeks postpartum. Recurrence risk 45-90% in subsequent pregnancies. Avoid estrogen-containing contraception (may trigger cholestasis). Counsel about recurrence; monitor early in future pregnancies. Long-term: slightly increased risk of hepatobiliary disease. Screen for hepatitis C if not done. Genetic component: ABCB4, ABCB11 mutations predispose.